All Stories

  1. Closing the UK care home data gap – methodological challenges and solutions
  2. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study
  3. Accuracy of Telephone-Based Cognitive Screening Tests: Systematic Review and Meta-Analysis
  4. Who Is Classified as Untestable on Brief Cognitive Screens in an Acute Stroke Setting?
  5. Social engagement after stroke – is it relevant to cognitive function? A cross-sectional analysis of UK Biobank data
  6. Accuracy of the short‐form Montreal Cognitive Assessment: Systematic review and validation
  7. Commentary: Evaluating the Landscape of Clinical Research in Neurosurgery
  8. Stroke prediction and the future of prognosis research
  9. When is Alzheimer’s not dementia—Cochrane commentary on The National Institute on Ageing and Alzheimer’s Association Research Framework for Alzheimer’s Disease
  10. Social engagement after stroke – is it relevant to cognitive function? A cross-sectional analysis of UK Biobank data
  11. Variability of functional outcome measures used in animal models of stroke and vascular cognitive impairment – a review of contemporary studies
  12. Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials
  13. Predicting Discharge to Institutional Long-Term Care After Stroke: A Systematic Review and Metaanalysis
  14. Sit to stand activity during stroke rehabilitation
  15. The effect of different combinations of vascular, dependency and cognitive endpoints on the sample size required to detect a treatment effect in trials of treatments to improve outcome after lacunar and non-lacunar ischaemic stroke
  16. Cochrane Dementia Group Turns 21—Older and (Slightly) Wiser
  17. Association between cognition and gene polymorphisms involved in thrombosis and haemostasis
  18. Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research
  19. Associations with publication and assessing publication bias in dementia diagnostic test accuracy studies
  20. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting
  21. Informant single screening questions for delirium and dementia in acute care – a cross-sectional test accuracy pilot study
  22. ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
  23. Single screening questions for cognitive impairment in older people: a systematic review
  24. Test Accuracy of Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke
  25. Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry
  26. Cross-cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO
  27. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting
  28. Cog-4 Has Limited Diagnostic Test Accuracy and Validity for Cognitive Assessment in Stroke Survivors
  29. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative
  30. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations
  31. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation
  32. The Dilemma of Treating Subclinical Hypothyroidism: Risk that Current Guidelines Do More Harm than Good
  33. Feasibility and Diagnostic Accuracy of Early Mood Screening to Diagnose Persisting Clinical Depression/Anxiety Disorder after Stroke
  34. Improving the Efficiency of Stroke Trials
  35. How Well Do Standard Stroke Outcome Measures Reflect Quality of Life?
  36. Test Accuracy of Short Screening Tests for Diagnosis of Delirium or Cognitive Impairment in an Acute Stroke Unit Setting
  37. The Cochrane Collaboration and geriatric medicine
  38. Management of blood pressure in acute stroke
  39. Questionnaire assessment of usual practice in mood and cognitive assessment in Scottish stroke units
  40. Response to Letter Regarding Article, “Prestroke Modified Rankin Stroke Scale Has Moderate Interobserver Reliability and Validity in an Acute Stroke Setting”
  41. Diabetes control in older people
  42. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies
  43. The Modified Graeb Score
  44. Assessment scales in stroke: clinimetric and clinical considerations
  45. Reliability (Inter-rater Agreement) of the Barthel Index for Assessment of Stroke Survivors
  46. Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review
  47. Principles of rehabilitation of older people
  48. Prestroke Modified Rankin Stroke Scale Has Moderate Interobserver Reliability and Validity in an Acute Stroke Setting
  49. Cardiac Ageing and Systemic Disorders
  50. Planning Cardiovascular Investigations and Management of Older People
  51. Novel lytics, novel imaging: a new treatment strategy in stroke?
  52. Subclinical thyroid disorders
  53. Responses to acute stroke: beyond urgent imaging and systemic thrombolysis, where to now?
  54. Cognitive and Mood Assessment in Stroke Research
  55. Cardiac Ageing and Systemic Disorders
  56. Nonpharmacological Interventions for Caregivers of Stroke Survivors
  57. Properties of Proxy-Derived Modified Rankin Scale Assessment
  58. Making the call: is telestroke cost effective?
  59. Non-pharmacological interventions for caregivers of stroke survivors
  60. Physical Activity in the Prevention and Treatment of Stroke
  61. Functional assessment in older people
  62. Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta‐analyzes
  63. Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐Analysis
  64. Post-acute care and secondary prevention after ischaemic stroke
  65. Barthel Index for Stroke Trials
  66. Do integrated stroke services impact on the ‘cost’ of stroke?
  67. Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase
  68. Long-Term Outcome following Attendance at a Transient Ischemic Attack Clinic
  69. Neckties and Cerebrovascular Reactivity in Young Healthy Males: A Pilot Randomised Crossover Trial
  70. Reliability of Structured Modified Rankin Scale Assessment
  71. Emergency Hospital Admissions from Care-Homes: Who, Why and What Happens? A Cross-Sectional Study
  72. Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control
  73. Application of quality-of-life measurements in clinical trials and in clinical practice for gynecologic cancer patients
  74. Acute ‘strokenomics’: efficacy and economic analyses of alteplase for acute ischemic stroke
  75. The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial
  76. Reliability of the Modified Rankin Scale
  77. Functional Outcome Measures in Contemporary Stroke Trials
  78. Response to Letter by Ray et al
  79. ABCD2 Scores and Prediction of Noncerebrovascular Diagnoses in an Outpatient Population
  80. Exploring the Reliability of the Modified Rankin Scale
  81. Evidence-based stroke rehabilitation: an expanded guidance document from the european stroke organisation (ESO) guidelines for management of ischaemic stroke and transient ischaemic attack 2008
  82. A recognition tool for transient ischaemic attack
  83. Hyperglycaemia in Acute Stroke – To Treat or Not to Treat
  84. Deriving Modified Rankin Scores From Medical Case-Records
  85. Variability in Modified Rankin Scoring Across a Large Cohort of International Observers
  86. Hypertension in acute stroke
  87. A link between lunar phase and medically unexplained stroke symptoms: An unearthly influence?
  88. Response to Letter by Proctor
  89. Advances in Emerging Therapies 2007
  90. Past, present and future of alteplase for acute ischemic stroke
  91. The Continued Yin and Yang of Uric Acid
  92. Time Spent at Home Poststroke
  93. European Stroke Conference, Glasgow, UK, May 29–June 1, 2007
  94. Reliability of the Modified Rankin Scale
  95. Response to Letter by Quinn et al
  96. Initial Experience of a Digital Training Resource for Modified Rankin Scale Assessment in Clinical Trials
  97. Acute stroke: we have the treatments and we have the evidence – we need to use them
  98. There is no evidence of an association in children and teenagers between the apolipoprotein E ɛ4 allele and post‐traumatic brain swelling